Tom Brady and Linda Yaccarino are leading a $200 million funding push for eMed, valuing the digital-health startup at more than $2 billion. The round follows a plan to sell employer programmes that pair GLP-1 drugs with AI-driven clinical oversight. EMed charges employers $25 a month per covered person and asks employees to pay $99 a month for medication and clinical support. Brady calls the drugs a "kick start," while Yaccarino links caregiver health to patient outcomes and employer costs.

Big raise for a workplace health play

The $200 million round cements eMed as a large private player in employer health. EMed now has a valuation above $2 billion, the company said. Investors see a market in offering GLP-1 medications through employers.

The strategy is simple. Employers pay a fixed fee. Employees pay a monthly charge that covers drugs and clinical guidance.

EMed markets that package to large employers and healthcare systems. The aim is to lower long-term chronic-disease spending by combining medicine, virtual care and AI tools.

How the programme is structured

EMed’s employer model charges $25 a month per covered person.

Employees who join the programme pay $99 a month for their medication and clinical support. Those are the figures the company has set for the offering.

The drugs involved are GLP-1 therapies. Examples include drugs such as Ozempic and Mounjaro, which are widely discussed in clinical and commercial markets.

EMed adds remote clinical oversight and coaching to the prescription.

Tom Brady, eMed co-owner and founding chief wellness officer, framed the medicines as a starting point. "This isn't about shortcuts for anybody. This is about a well-delivered program for people to kickstart their health journey," Brady said. He said the approach combines medication with accountability and clinical guidance.

Mastheads

Claims on outcomes and cost

EMed has published outcome figures for its members. The company says members see an average weight loss of 24 pounds. It also says 96% show reductions in pre-diabetes markers within six months and adherence exceeds 90%.

Linda Yaccarino, eMed chief executive officer, tied those outcomes to employer savings. "When the health of our caregivers declines, patient outcomes follow. A healthier healthcare workforce doesn't just benefit the workers, it results in better care for all of us," Yaccarino said. She also argued that chronic disease is a rising cost for employers.

Yaccarino noted a wider cost backdrop. She said chronic diseases could cost American businesses $2 trillion by 2030 if current trends continue. The implication is that programmes which lower chronic risks offer employers a path to reduce claims and lost productivity.

Who eMed is pitching to

EMed has emphasised healthcare employers as an early target. The company points to the size of the sector. This US healthcare industry employs more than 20 million people, the company noted, and those workers often face irregular hours and high stress.

Yaccarino told audiences that declining caregiver health harms patient care and organisational performance. The argument is that healthier staff can translate into better outcomes and lower operational disruption.

Beyond healthcare, eMed is pitching the package to employers more broadly. Linda Yaccarino said the company intends to deliver solutions to employers across the country, using AI and clinical teams to scale support.

The GLP-1 market has attracted huge attention. Industry estimates cited by company spokespeople have put it near a projected $150 billion market as demand grows. That scale explains investor interest.

But the model also faces questions. Cost is one. Even with the employer subsidy, employees still pay a monthly medication fee. That creates a barrier for lower-paid staff unless employers cover a larger share.

Another question is supply and appropriate prescribing. EMed stresses clinical oversight. The company says medical teams and AI tools guide use. That's meant to limit inappropriate prescriptions and manage side effects.

EMed plans to sell the programme to large employers first. The company frames the offer as a population-health product. It combines medication access, virtual care and data tools to measure outcomes and costs.

Brady said he wants to bring the kind of coaching and guidance he had as an athlete to people who lack that support. The business pitch is that scalable clinical support plus medication will reduce long-term employer expenses related to chronic disease.

Related Articles

EMed charges employers $25 a month per covered person, while employees pay $99 a month for medication and clinical support.

This article was created with AI assistance.